According to the American Lung Association, the ROS1 gene mutation occurs in about 1% to 2% of lung cancers and is more common in patients with little to no history of smoking. The AnHeart ...

During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, discussed the TRIDENT-1 trial and practical considerations for ...

Want to learn about a clinical trial targeting patients who have tumours with ALK or ROS1 gene alterations?' reads a recent tweet from @NovartisCancrUS, Novartis' Twitter channel dedicated to its ...

So far, eight types of lung cancer gene mutations have been identified, including epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS1, and KRAS. The PANAMutyper ROS1 ...

The patient's cancer originally had a ROS1 gene rearrangement, which made it responsive to lorlatinib. But as time went on, the cancer started to grow again, and tests revealed a new genetic ...

Human epidermal growth factor receptor 2 (HER2) The human epidermal growth factor receptor 2 (HER2) gene mutation is involved in 1% to 4% of NSCLCs. About 1% to 2% of NSCLCs have the ROS1 mutation.

As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market segment. While competition from other TRK inhibitors ...